Aozhou Wu
Education
Ph.D. and M.H.S., epidemiology, M.H.S, biostatistics, M.S.E, computer science, Johns Hopkins University; M.B., laboratory medicine, B.S., statistics, Peking University
Summary of Experience
Dr. Wu is an epidemiologist specializing in study design, statistical methods, and pharmacoepidemiology, with expertise in health economics and outcomes research (HEOR) across diverse disease areas such as cardiovascular diseases, oncology, neurology, nephrology, neuropathy-related diseases, and infectious diseases. Dr. Wu’s research encompasses a wide range of areas, including understanding the natural history and epidemiology of diseases, as well as evaluating the comparative effectiveness, safety profiles, and cost profiles of treatments. He is adept at applying advanced statistical methods, such as causal inference, statistical modeling, missing data imputation, and machine learning methods, to address analytical challenges in health care. His case work involves indirect treatment comparisons (e.g., network meta-analyses and matching-adjusted indirect comparisons), real-world database analyses, comparative effectiveness research using clinical trial data, surrogate outcome analyses, and health economic evaluation (e.g., cost-per-outcome and cost-effectiveness analyses). Dr. Wu’s research has been published in peer-reviewed journals, including JAMA, JAMA Internal Medicine, JAMA Neurology, the American Journal of Kidney Diseases, and Neurology, and his research findings have been presented at international conferences. He has also served as a peer reviewer for multiple journals.
-
Indirect Treatment Comparison (Itc) of the Efficacy of Vutrisiran and Tafamidis for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Expert Opinion on Pharmacotherapy, 2023
2023 -
A Matching-Adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma
European Urology Oncology, 2023
2023McGregor B, Geynisman DM, Burotto M, Suárez C, Bourlon MT, Barata PC, Gulati S, Huo S, Ejzykowicz F, Blum SI, Tejo VD, Hamilton M, May JR, Du EX, Wu A, Kral P, Ivanescu C, Chin A, Betts KA, Lee CH, Choueiri TK, Cella D, Porta C
-
Value of Remission in Patients with Rheumatoid Arthritis: A Targeted Review
Advances in Therapy, 2022
2022 -
CKD Progression and Economic Burden in Individuals with CKD Associated with Type 2 Diabetes
Kidney Medicine, 2022
2022Mullins CD, Pantalone KM, Betts KA, Song J, Wu A, Chen Y, Kong SX, Singh R
-
Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma
Journal of Comparative Effectiveness Research, 2021
2021Parikh ND, Marshall A, Betts KA, Song J, Zhao J, Yuan M, Wu A, Huff KD, Kim R
-
Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era
Current Medical Research and Opinion, 2021
2021